Innovations in the Biotech and Pharma Industries in India |
ICMR HOME | Case Studies Collection
» Innovation Case Studies Please note: This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source. |
||||
"The potential for Indian BioPharma segment is huge. With the implementation of WTO and patents regime in 2005, Indian companies would not be able to do backward engineering of the drugs, so they are focusing on in-house R&D. The growth prospects are bright as many contract research organizations are coming up. Besides, a large number of foreign pharma companies are setting up their R&D divisions here." - Dr. S D Ravetkar, Senior director, Serum Institute of India.1 "The trend seems to be that more and more pharma companies are diversifying into the biotech sector. It would be prudent to have a synergy between the pharma and biotech companies to avoid cannibalization and killing of effective products." - Dr Krishna M Ella, chairman and managing director of the Hyderabad-based Bharat Biotech International Limited (BBIL).2 Introduction
The GoI has more than doubled the biotech research Plan outlay, from Rs 6.22 billion in the Ninth Plan (1997-2002) to Rs 14.5 billion in the 10th Plan (2002-2007). Apart from funding, the GoI has eased the regulatory framework by approving genetically modified crops3 and recombinant-DNA products (rDNA)4; as well as ethical stem cell research5.
Innovations in the Biotech and Pharma Industries in India - Next Page>>
1] Rolly Dureha, "BioPharma longs for scientists",' www.biospectrumindia.com, February 12, 2004. |
Case Studies Links:-
Case Studies,
Short Case Studies,
Simplified Case Studies.
Other Case Studies:-
Multimedia Case Studies,
Cases in Other Languages.
Business Reports Link:-
Business Reports.
Books:-
Textbooks,
Work Books,
Case Study Volumes.